The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 37 | — | 20.1x | Near average | |
Growth | 81 | 138.9% | 5.6% | Above average | |
Quality | 35 | -110.4% | 7.6% | Near average | |
Safety | 33 | 0.5x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Prelude Therapeutics Incorporated is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Prelude Therapeutics Incorporated shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Prelude Therapeutics stock shows a state of complete stability in the target price at $8, with an absence of any price revisions during the periods (day, week, month). This consistency reflects the lack of new catalysts or material updates from analysts, as the current consensus is limited to only one analyst, indicating a low level of research coverage for the stock at the present time.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.